Dispatch · June 27, 2026 · 8 min read

Summer 2026 Body Comp Update: What 6 Months of GLP-1 Data Shows for Men

Six months into 2026, the body composition story for men on GLP-1 medications has never been clearer — or more encouraging. A wave of new research, conference presentations, and real-world clinical data has answered questions that men have been asking since these medications went mainstream: how much of the weight I'm losing is fat versus muscle?

The short answer: the ratio is better than most men feared, and it's getting better as clinicians refine their protocols.

The Fat-to-Lean Mass Ratio: Updated Numbers

A major meta-analysis published in the International Journal of Obesity in April 2026 confirmed what body composition substudies had suggested: GLP-1 receptor agonists are effective at reducing fat mass, though strategies to preserve skeletal muscle mass — resistance training and adequate protein — should be integral to treatment.

The SURMOUNT-1 body composition substudy of tirzepatide reported a favorable split: approximately 75% of weight reduction came from fat mass and 25% from lean mass. At week 72, fat mass dropped roughly 34% while lean mass fell about 11% from baseline. In practical terms, about three pounds of fat came off for every pound of lean tissue.

For semaglutide, the split tends to run closer to 60-65% fat and 35-40% lean mass in studies without structured exercise programs. That gap between the two drugs narrows significantly when patients follow resistance training protocols — a point researchers have emphasized repeatedly this year.

Why Men Have a Body Comp Advantage

Men typically carry more muscle mass at baseline than women, which creates a larger metabolic buffer during weight loss. Higher baseline testosterone — even when reduced by obesity — supports muscle protein synthesis during caloric deficit. And men tend to carry a greater proportion of visceral (belly) fat, which responds particularly well to GLP-1 treatment.

A June 2026 review in Pharmaceuticals found that the future of obesity treatment lies not in greater weight loss per se, but in achieving "better weight loss" — defined as metabolically favorable, functionally responsible, and clinically sustainable. For men, this means tracking body composition alongside the scale number.

The Protocol That's Working in 2026

The most effective male body composition programs in mid-2026 share three elements:

Smart clinicians in 2026 are treating dose titration as a body composition lever, not just a tolerability one. Aggressive dose escalation produces a steeper energy deficit and faster weight loss, but pulls more lean mass along with it. A measured approach — moving up only when the current dose is tolerated and body composition targets are on track — produces better long-term results.

What DXA Scans Are Showing at 6 Months

Men who combine GLP-1 therapy with consistent resistance training and adequate protein are showing fat loss percentages in the 80-85% range of total weight lost — significantly better than the 60-65% seen in sedentary patients on semaglutide. The difference is the behavior, not the drug.

Grip strength — a key predictor of overall health and longevity in men — is largely maintained in active patients and tends to improve as body weight decreases and relative strength increases.

The Summer 2026 Takeaway

The body composition data at mid-2026 tells a clear story: GLP-1 medications are effective fat-loss tools, and the muscle-preservation question has been answered — not by the drugs themselves, but by what men do alongside them. Resistance training and protein are not optional add-ons. They are the difference between losing weight and improving body composition.